Ex-Google, Amazon Execs-Founded SwishX Launches World’s Ist Agentic AI Platform for Pharma & Medtech

• Bengaluru-based startup seed-funded for $2.2 million backed by Powerhouse Ventures, Blume Ventures, Sadev Ventures, Atrium Ventures, and others
• Targets $5M ARR and 100+ enterprise clients
• Plans expansion across emerging markets including Latin America, Southeast Asia, Middle East, Africa, and Eastern Europe

SwishX today announced its launch, introducing the World’s first Agentic AI platform built exclusively for pharmaceutical and medtech companies, aimed at transforming sales, marketing, distribution, and business growth through artificial intelligence.

The Bengaluru-headquartered startup is targeting $5 million in contracted ARR and 100+ Enterprise clients by end of current FY 2026-27, and plans expansion into Latin America, Southeast Asia, the Middle East, Africa, and Eastern Europe. SwishX has also raised $2.2 million in seed funding backed by Powerhouse Ventures, Blume Ventures, Sadev Ventures, Atrium Ventures, and other investors. These emerging markets, along with India, represent a $400 billion pharma and medtech opportunity, with commercial operations expected to grow to $770 billion by 2033 at a CAGR exceeding 12%.

India, dubbed as the ‘pharmacy of the world’, alone supplies 20% of the world’s medicines, and exports to over 200 countries, and is home to the highest number of US FDA-approved manufacturing plants outside the United States. However, most companies still lack real-time visibility into key business questions - which public tenders out of thousands they have a real shot at winning, where is the revenue leakage happening, what is actually selling at the retailer level, whether marketing efforts to engage doctors are generating results? All this is part of a long-standing problem in the pharma industry, where many critical commercial decisions still depend on spreadsheets, disconnected software, manual workflows, and delayed reporting. SwishX aims to address these gaps through AI Agent-led solutions and improve revenue outcomes by up to 30%.

SwishX’s specialized AI Agents capture siloed data, automate business workflows, learn nuances of every decision and build a functional memory to help business teams accelerate their execution.

While starting with India, SwishX is helping the pharma companies to further grow in other countries as well by combining AI with local market data of different countries. The platform autonomously evaluates thousands of tenders globally, surfaces most high-probability win opportunities, analyzes complex 500+ pages documents, recommends likely winning pricing, and drafts proposals within minutes. It also enables quick conversion of long marketing PDFs into highly engaging personalized video reels for doctors - reducing the time taken from weeks to just one day.

Dushyant Sapre, Founder & CEO, SwishX, said, “India’s pharma sector, recognized as the Pharmacy of the World, drives revenues of over USD 65 billion and Emerging Markets combined drive USD 400 billion while distributing into over 200 countries. Manufacturing and R&D have become genuinely world-class, but how these companies sell, market, and distribute, is still stuck in the past. Companies often struggle to know where losses are happening, what is selling, which tenders matter most, or how effectively teams are executing in the market. AI Agents change that completely. The next big transformation in this industry is not going to happen in the lab. It is going to happen in how these companies go to market. For the first time, companies can move to real-time autonomous execution.”

SwishX is purpose built specifically for the complexity of emerging markets. India alone has over 1.2 million pharmacies, compared to just ~1,00,000 in the US. Additionally, 30-60% of procurement happens through government tenders, rate contracts and generic competition is significantly more intense.

SwishX is being launched at a time when pharma companies are accelerating AI adoption with industry estimates suggesting that AI could unlock $60–110 billion in annual value globally in this sector.

SwishX is not a traditional CRM or reporting tool, but a complete Agentic AI-platform combining intelligence and execution. Over the long term, SwishX aims to build a vertically integrated AI system for the entire value chain of life sciences companies - faster generic and biosimilar drug discovery, drug development, and autonomous multi-market commercial execution. For now, SwishX is anchored where the pain is most immediate and most measurable.

About SwishX

SwishX is a Bengaluru-based Agentic AI startup building “outcome first” solutions for pharmaceutical, medtech, and life sciences companies across Emerging Markets. It is the world's first agentic AI platform designed as a system of action for the pharma industry, that not only turns complex data into clear decisions, but also helps teams execute those decisions faster and at scale using autonomous AI agents.

Built for the complexity of emerging markets, SwishX helps pharma companies move beyond spreadsheets and fragmented systems. It enables companies to improve sales execution, strengthen marketing and channel engagement, streamline distribution networks, and automate critical workflows through autonomous AI agents, proprietary data sets and real-time market intelligence.

The platform spans 4 products: Tender IQ (Agentic AI Tender & RFP Automation), Contract IQ (Agentic AI Hospital Rate Contract Automation), Marketing IQ (Agentic AI HCP & Rep Engagement), Channel IQ (Agentic AI Channel Engagement). The company is SOC-2 compliant with data encryption in transit and rest.

Starting with India, the company plans to expand across Latin America, Southeast Asia, the Middle East, and Africa, with a long-term vision to build a vertically integrated AI platform for the life sciences sector across the full business lifecycle: from generic drug development to multi market distribution.

Eli Lilly Launches Mounjaro® in India

• Adults taking Mounjaro® with diet and exercise in a controlled clinical trial lost on average 21.8 kg. at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg) over a period of 72 weeks. Individual results may vary
• Mounjaro® delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials
• Mounjaro®, a once-weekly injection is a prescription medicine and should be used under medical advice

Eli Lilly and Company (India) today announced the launch of Mounjaro® in single-dose vial presentation following the marketing authorization from the Central Drugs Standard Control Organization (CDSCO). It is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

Mounjaro® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Mounjaro® is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

“The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India. Lilly is committed to collaborating with the government and industry to promote awareness and improve the prevention and management of these diseases,” said Winselow Tucker, President and General Manager, Lilly India. “Our mission to making life better for people living with obesity and diabetes in India is reflected in our efforts to accelerate the introduction of innovative medicines. The launch of Mounjaro® demonstrates our ongoing support to this mission and our shared vision of a healthier nation.”

Tirzepatide was evaluated in two robust global clinical development programs: the SURMOUNT - 1 trials for chronic weight management and the SURPASS trials for type 2 diabetes.

In SURMOUNT-1, a study in 2,539 adults with obesity, or excess weight and weight-related medical problems not including diabetes, people taking Mounjaro® as an adjunct to diet and exercise experienced substantial weight loss compared with placebo at 72 weeks. At the highest dose (15 mg), people taking Mounjaro® lost on average 21.8 kg, while at the lowest dose (5 mg), people lost on average 15.4 kg (compared to 3.2 kg on placebo).1,2 Additionally, 1 in 3 patients taking Mounjaro® at the highest dose lost over 26.3 kg (25% of body weight), compared to 1.5% on placebo, according to data not controlled for type 1 error.1,2 In summary, Mounjaro® significantly reduced weight by up to 21.8 kg in the SURMOUNT-1 study.

In phase 3 SURPASS program, efficacy was evaluated for Mounjaro® 5 mg, 10 mg and 15 mg used alone or in combination with commonly prescribed diabetes medications, including metformin, SGLT2 inhibitors, sulfonylureas and insulin glargine. Participants in the SURPASS program achieved average A1C reductions between 1.8% and 2.1% for Mounjaro® 5 mg and between 1.7% and 2.4% for both Mounjaro® 10 mg and Mounjaro® 15 mg over the period of 40 weeks.3-6 Overall, the program demonstrated that Mounjaro®, whether used alone or with other diabetes medications, reduced A1C by up to 2.4%.

India has about 101 million people living with diabetes and nearly half of these in the adult patients category are being inadequately treated with suboptimal glycemic control.10 Obesity, a chronic relapsing disease, is a major risk factor for diabetes, is linked to over 200 health complications, including hypertension, dyslipidemia, coronary heart disease, and obstructive sleep apnea.11,12 As of 2023, adult obesity prevalence in India stood at around 6.5%, affecting nearly 100 million people.

“Obesity and diabetes are recognized as serious conditions linked to various life-limiting health complications, making effective and sustained treatment critical. We are thrilled to introduce Mounjaro® in India to address these unmet medical needs. Mounjaro® may offer a new approach to metabolic health management, providing healthcare providers with an innovative option to treat these diseases.” said Dr. Manish Mistry, Senior Medical Director, Lilly India.

Once-a-weekly, prescription-based medicine, Mounjaro® is a single molecule that selectively binds to and activates both GIP and GLP-1 receptors, which are natural incretin hormones. In a glucose-dependent manner, Mounjaro® improves first phase and second phase insulin secretion, and reduces glucagon levels; it also improves insulin sensitivity and delays gastric emptying14. GIP receptors and GLP-1 receptors are both expressed in important areas of the brain that regulate appetite. Mounjaro® reduces food intake, body weight, and decreases fat mass by regulating appetite; moreover, Mounjaro® has been demonstrated to regulate lipid utilization.14 Mounjaro® (tirzepatide) has already had a tremendous impact on millions of people living with type 2 diabetes and obesity, respectively.

Venus Remedies Secures Exclusive In-Licensing Rights to Develop and Commercialize MET-X in India

• MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies and could be game-changing for patients suffering from Gram-negative, MBL-resistant infections
• Meropenem resistance in India is as high as 62-87%, with up to 50% linked to MBL prevalence, according to ICMR report
• India faces a significant burden of MBL-producing pathogens in hospital settings, and no approved MBL inhibitors currently exist in the country

Venus Remedies Ltd. (NSE: VENUSREM, BSE: 526953), a leading Indian pharmaceutical company renowned for its longstanding expertise in combatting antimicrobial resistance (AMR), today announced that it has entered into an exclusive license agreement with Infex Therapeutics, a UK-based anti-infectives specialist for the clinical development of MET-X. This agreement authorizes Venus Remedies to spearhead the clinical development, registration, and commercialization of MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor. The initial development phase will focus on integrating MET-X with meropenem to tackle drug-resistant Gram-negative bacteria, with Venus Remedies holding exclusive marketing rights within India.

In India, meropenem resistance is reported to be as high as 62-87% in WHO critical priority pathogens like K. pneumoniae and A. baumannii as per the ICMR’s Antimicrobial Resistance Research and Surveillance Network-Annual report 2023, with as high as 50% being directly attributable to MBL prevalence.

Under the terms of the agreement, Venus Remedies will commence with a Phase I trial involving healthy volunteers in India, evaluating MET-X in combination with meropenem. Following successful Phase I outcomes, the focus will shift to Phase II/III trials targeting drug-resistant Complicated Urinary Tract Infections (cUTIs), prevalent in hospital settings.

This strategic move is aligned with Venus Remedies’ extensive experience in antibiotic R&D and critical care, enhancing its leadership in the Indian critical care landscape. The company’s formidable position in meropenem marketing and manufacturing will facilitate the integration of MET-X into existing and prospective antibiotic strategies.

All trials conducted in India will adhere to international standards, compliant with regulations from the FDA, EMA, and MHRA, which will also support further development and global commercialization efforts for MET-X. The agreement grants both Infex Therapeutics and Venus Remedies the option to expand their collaboration to include other MET-X/beta-lactam combinations under mutually agreed terms.

MET-X is Infex Therapeutics’ broad spectrum MBL-inhibitor, targeting Gram-negative bacteria. These pathogens produce MBL enzymes to deactivate beta-lactam antibiotics, such as meropenem, and evade antibiotic clearance of disease. MET-X blocks MBL resistance, restoring antibiotic activity. The drug is being developed to be one of the first broad-spectrum MBL inhibitors to address a wide range of bacterial species and MBL-resistant strains, such as E.coli and K.pneumoniae. The treatment has shown best-in-class performance in animal studies to date. The development of new agents to overcome MBL antibiotic resistance in such Gram-negative bacteria is a World Health Organisation (“WHO”) critical priority.

Mr. Saransh Chaudhary, President, Global Critical Care, Venus Remedies Ltd and CEO, Venus Medicine Research Centre, said: “This early-stage introduction of MET-X into the Indian market leverages our decades-long dedication to AMR-focused R&D and our prominent role in critical care and antibiotic therapies. This partnership is perfectly poised to enhance our antibiotic arsenal with meropenem and explore further beta-lactam combinations, ensuring high-quality research and a significant market presence.”

Mr. Pawan Chaudhary, Chairman and Managing Director, Venus Remedies Ltd, added, “The in-licensing of MET-X is a major step forward in providing breakthrough solutions for drug-resistant infections, a serious threat to India’s healthcare ecosystem. Our aim is to develop an effective solution against MBL-producing pathogens, fulfilling a critical healthcare need and continuing our commitment to transformative therapies and sustained innovation in critical care.”

India faces a significant burden of MBL-producing pathogens in hospital settings, and no approved MBL inhibitors currently exist in the country. The development and exclusive in-licensing of MET-X underscores Venus Remedies’ commitment to providing a cutting-edge solution where it is needed most and creating long-term value for stakeholders.

Dr. Peter Jackson, CEO of Infex Therapeutics, said: “I am delighted about this agreement with Venus Remedies, which will facilitate the comprehensive clinical development of our MET-X program in India. By leveraging Venus Remedies’ robust expertise in critical care antibiotics, we can accelerate MET-X as our second clinical-stage drug program. Crucially, the international standards of these trials will also support future regulatory filings in the UK, U.S., Europe, and other global markets. MET-X has shown best-in-class performance in preclinical studies and could be game-changing for patients suffering from Gram-negative, MBL-resistant infections.”

About Venus Remedies Ltd (venusremedies.com)

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 90+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. The company holds the GMP approvals from European- GMP (INFARMED), PIC/S (Malaysia & Ukraine), SAHPRA, UNICEF, TGA, INVIMA & WHO-GMP, alongside key ISO certifications for quality, environmental, and occupational health and safety management.

Central to its mission, Venus Remedies is a frontrunner in combating antimicrobial resistance (AMR) through its dedicated research division, Venus Medicine Research Centre (VMRC). The company is pivotal in developing advanced antibiotics and β-lactam/β-lactamase inhibitor combinations aimed at tackling multidrug-resistant pathogens. Its notable initiatives like GASAR provide essential data on antibiotic resistance, while the PLEA Trust fosters antibiotic stewardship. As an influential member of the AMR Industry Alliance, India AMR Innovation Hub, and Vivli AMR Registry, Venus Remedies shapes global AMR research and policy. Through strategic collaborations with academic and health organizations worldwide, the company enhances AMR surveillance and supports innovative drug development, affirming its leadership in global healthcare.

About Infex Therapeutics (www.infextx.com)

Infex Therapeutics Holdings plc is a leader in critical-priority infectious diseases, with a broad and diverse pipeline of innovative best-in-class and first-in-class drug candidates to address the urgent global shortage of novel anti-infective treatments. The Company is building a differentiated pipeline through in-house drug discovery, acquisition, co-development and in-licensing of early stage/pre-clinical candidates, developing them to clinical proof of concept before licensing to commercial pharma partners.

Key Milestone in India’s Clinical Research Ecosystem: ICMR To Begin First-In-Human Clinical Trials for 4 Promising Molecules

The Indian Council of Medical Research (ICMR) has recently signed Memoranda of Agreements (MoAs) with several industry and academic partners to advance First-in-Human Phase-1 clinical trials.

This initiative marks a key milestone in India's clinical research ecosystem, focusing on four promising molecules:

1. Multiple Myeloma: Collaborative research with Aurigene Oncology Limited.

2. Zika Vaccine: Development in partnership with Indian Immunologicals Limited.

3. Seasonal Influenza Vaccine: Trials coordinated with Mynvax Private Limited.

4. CAR-T Cell Therapy: Advancement study for chronic lymphocytic leukemia with ImmunoACT.

This collaboration aims to establish India as a leader in the clinical development of pharmaceutical agents, ensuring affordable and accessible cutting-edge treatments for all citizens.

First-in-Human (FIH) clinical trials are a critical phase in the development of new medical treatments. FIH trials are the first time a new drug or treatment is tested in humans. They primarily focus on assessing the safety and tolerability of the treatment. These trials help determine the appropriate dosage range for the treatment, identifying the maximum tolerated dose and any potential side effects.

FIH trials study how the drug is absorbed, distributed, metabolized, and excreted in the body (pharmacokinetics) and its biological effects (pharmacodynamics). Successful FIH trials pave the way for subsequent phases of clinical trials, which further evaluate the efficacy and safety of the treatment in larger populations.

These trials are essential for ensuring that new treatments are safe and effective before they become widely available to patients.

By collaborating with industry and academic partners, the ICMR can expedite the development of new treatments, ensuring they reach patients faster.

Besides, Industry-Partnerships can reduce the financial burden on any single entity, making the research and development process more cost-effective. This can lead to lower costs for the end treatments. Moreover, combining the strengths of industry and academia brings together a wealth of knowledge and resources, improving the quality and efficiency of the research.

Developing treatments within India can reduce dependency on international pharmaceuticals, potentially lowering costs and improving accessibility for Indian citizens. Successful FIH trials can streamline the regulatory approval process, ensuring that safe and effective treatments are available to the public sooner.

By focusing on diseases like multiple myeloma, Zika, and chronic lymphocytic leukemia, these trials address significant public health challenges, aiming to provide cutting-edge treatments that are both affordable and accessible.

This initiative not only strengthens India’s position in global clinical research but also promises to make advanced medical treatments more accessible to its population.

Union Health and Family Welfare Minister, Shri J P Nadda, commended the strategic collaboration between ICMR and prominent industry and academic partners, emphasizing it as a key milestone in the pursuit of affordable and accessible cutting-edge treatments for all citizens. He noted that this initiative positions India to emerge as a global leader in healthcare innovation.

Dr. Rajiv Bahl, Secretary, Department of Health Research & Director General, ICMR, emphasized the transformative potential of the project, stating, “This collaboration reflects our commitment to advancing clinical research in India through strategic public-private partnerships. Establishing Phase 1 clinical trial infrastructure is a key component in fostering the development of indigenous molecules and cutting-edge treatments. Our vision is to expand this network further, ensuring that India continues to lead in the development of innovative and affordable healthcare solutions.”

Cipla Gets Approval to Introduce Zemdri® (Plazomicin) Injection in India, for Treatment of cUTR

Cipla Limited (BSE: 500087; NSE: CIPLA EQ) received approval from the Central Drugs Standard Control Organization (CDSCO) to market the novel antibiotic plazomicin in India.

Plazomicin is a new intravenous (IV) aminoglycoside indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis. UTIs are a global health problem affecting approximately 150 million patients each year. The emergence of drug resistant uropathogens has posed a big challenge in management of UTIs. A pivotal clinical trial and in-vitro studies demonstrated efficacious and safe results in comparison to meropenem. It also highlighted plazomicin’s ability to retain in-vitro activity against strains resistant to older aminoglycosides. Plazomicin's introduction in India underscores Cipla's proactive response to the urgent global challenge of antimicrobial resistance (AMR).

Cipla USA Inc., a subsidiary of Cipla, holds the patent for plazomicin sulfate, an intravenous aminoglycoside administered once daily. The company possesses global rights for this molecule, excluding Greater China, and is the innovator of the brand called ZEMDRI®. Cipla USA Inc. currently markets the product in the USA, where it received approval from the US FDA in 2018. ZEMDRI®, for an appropriate time, held the designation of a new technology add-on payment (NTAP) status granted by the US Medicare and Medicaid Services (CMS) - specifically for hospital administration.

Commenting on the approval, Mr. Umang Vohra, Managing Director, and Global CEO, Cipla, said, “The introduction of plazomicin in India is an important step forward in bringing solutions that address the evolving healthcare challenges of our time. Cipla remains steadfast in building capabilities and driving stewardship activities to counter the global threat of AMR. Our focus remains on developing a robust antimicrobial portfolio, forging partnerships with thought leaders and industry alliances to ensure global access to antimicrobial drugs for a healthier life.”

As a part of Cipla’s extensive efforts to address antimicrobial resistance (AMR), the company is also implementing EHS management programs, strengthening wastewater and solid waste management, adhering to local environmental regulations, and providing vital training towards its sustainability initiatives.

Cipla Makes Additional Investment in GoApptiv to Hold 22.99% Stake in the Health/Pharma Tech Company

Strengthens investment in channels of the future to expand patient reach

Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announced today that it has agreed to further invest INR 42 crore (approx.) in digital tech company GoApptiv Private Limited (hereafter referred to as “GoApptiv”).

Founded in 2016, GoApptiv aims to revolutionize the healthcare and pharmaceutical space in India with its unique 'phygital' model that provides quality healthcare access to extra-urban and rural India.

In line with Cipla’s ambition to strengthen investments in channels of the future, this additional investment will further expand Cipla’s presence across the healthcare continuum, especially to the underserved population by enabling greater access to lifesaving treatments.

With the completion of this deal, Cipla’s total stake in GoApptiv will increase to 22.99% on a fully diluted basis. This is Cipla’s third investment in GoApptiv, which will be made in a combination of equity shares and compulsorily convertible preference shares. GoApptiv has experienced significant expansion in underpenetrated areas and product lines following prior investments by Cipla in 2022 and 2020.

Commenting on the development, Umang Vohra, MD Global CEO, Cipla Limited, said, “Our long-standing partnership with GoApptiv has helped us increase penetration in underserved rural areas of India and address critical healthcare gaps where pharmaceutical coverage is limited. As we advance in the era of technology-driven healthcare, this expanded investment will not only enhance our collective abilities to deliver patient-centric solutions, but also furthers our digitisation agenda to drive Cipla’s next phase of growth.”

GoApptiv’s use of technology to provide quality and affordable healthcare aligns with Cipla's commitment to making a positive impact on communities through innovative solutions. Cipla plans to continue supporting GoApptiv through further investment rounds, solidifying their partnership in addressing healthcare disparities in underserved regions of India.

This year in July, GoApptiv incorporated a wholly-owned subsidiary company — ‘Pactiv Healthcare’— with an objective to handle the manufacturing, development, production, purchase, and sale of pharmaceutical, healthcare and wellness products to significantly benefit the Rural markets platform aims to drive agile market access, optimise patient experiences, deliver organisational growth and empower every stakeholder in the healthcare ecosystem. With its combination of proprietary technology and on-ground field force, GoApptiv claims to have been able to reach: 27 States, 200,000+ villages, 3,424 markets, 3,100 Tehsils, 618 districts.

The company explains – "The Indian Healthcare Industry is at the cusp of a "digital revolution". However, while physicians and patients are individually adapting to 'digital', healthcare companies have been slow to embrace innovation. Traditional pharma companies tend to implement digital solutions in silos, and even these limited efforts are focussed solely on urban markets. The reason for this is that, extra-urban and rural markets are extremely fragmented and highly unstructured, therefore setting these companies back with significant costs (major entry barrier). GoApptiv has taken a lead in developing "smart-shared platforms" that address this gap. The company's end-to-end solutions provide the digital infrastructure required to enable pharma companies to expand their footprint with cost efficiency and speed to market by leveraging economies of scale."

Wipro Working with AWS To Transform Lab Processes in the Life Sciences Industry

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, announced that it is working with Amazon Web Services (AWS) to redefine the future of lab processes in the life sciences industry. 

The life science and pharmaceutical industries have long struggled with outdated laboratory processes that hinder efficiency and increase costs. Lab technicians, lab associates, and medical specialists often find themselves performing tasks outside of their expertise due to the fragmentation of laboratory operations across various platforms. This lack of cohesion not only results in inefficiencies but also extends the time required to bring new drugs and products to market, subsequently increasing research and development expenses.

Recognizing these challenges, Wipro began working with AWS to create the Lab of the Future. This innovative solution addresses the root issues that have plagued the industry, offering a comprehensive, cloud-based platform that streamlines laboratory processes and enhances collaboration among stakeholders.

“Our vision with launching Lab of the Future, is to deliver holistic lab performance powered by generative AI, advanced analytics, and a consultative business first approach,” said Philippe Dintrans, Senior Vice President & Global Head of Domain & Consulting at Wipro Consulting.

Among the key challenges facing the Life Sciences industry today are decreasing ROI for R&D (R&D returns fell to 1.8% in 2019, down from 10% in 20101), increasing cost of bringing new drugs to the market, and the significant amount of time spent on data management, which takes 45% of data scientists’ time, according to recent surveys.2

By introducing the Lab of the Future, Wipro and AWS aim to empower the life sciences industry with a modern, efficient, and collaborative laboratory solution that has the potential to significantly reduce costs and accelerate the development of life-saving drugs and products.

Among 12 leading large-cap biopharma companies, R&D returns fell to 1.8% in 2019—down from 10% in 2010
^{1https://www.us.jll.com/en/views/real-estate-as-reagent-how-the-right-life-sciences-space-can-drive-innovation}
2https://www.datanami.com/2020/07/06/data-prep-still-dominates-data-scientists-time-survey-finds/

“Wipro has enhanced offerings for clients across the life sciences value chain and our latest Lab innovation with AWS further illustrates our commitment to helping our clients improve business outcomes and enable cost efficiency,” said Srini Rajamani, Senior Vice President & Sector Head – Consumer and Life Sciences at Wipro.

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading technology services and consulting company focused on building innovative solutions that address clients’ most complex digital transformation needs. Leveraging our holistic portfolio of capabilities in consulting, design, engineering, and operations, we help clients realize their boldest ambitions and build future-ready, sustainable businesses. With nearly 245,000 employees and business partners across 65 countries, we deliver on the promise of helping our clients, colleagues, and communities thrive in an ever-changing world. For additional information, visit us at www.wipro.com

Mankind Pharma Acquires Majority Stake in Upakarma Ayurveda

Manknd Pharma Limited has announced that one of its subsidiaries has acquired a majority stake in Upakarma Ayurveda Private Limited, a brand that is engaged in developing, manufacturing and selling ayurvedic and herbal products.

Upakarma Ayurveda offers products ranging from improving health and wellness to boosting immunity. It is driven by the vision to achieve overall well-being of the human body with a focus on body, mind, and lifestyle.

Upakarma Ayurveda has repositioned Shilajit as a health & wellness product, and sought to reimagine the stereotypical way Shilajit was perceived in the market as an aphrodisiac (sexual wellness product) for men. Upakarma Ayurveda has elucidated the cumulative benefits of Shilajit as an overall health rejuvenator and immunity booster.

Mankind Pharma’s decision to invest in Upakarma Ayurveda will empower the latter to strive to develop a wider range of products and offerings and penetrate the market leveraging the strong distribution network of Mankind Pharma.

On the occasion, Rajeev Juneja, the Vice Chairman and Managing Director of Mankind Pharma Limited, said, “The current lifestyle has become strenuous where people find it difficult to focus on their health. To fulfill their requirements, consumers are considering Ayurvedic remedies for long-term sustenance and boosting immunity over time. As Mankind Pharma works towards improving the healthcare of people, we have associated with Upakarma Ayurveda in order to cater to the emerging needs of consumers.”.

Being optimistic Vishal Kaushik the Founder & Managing Director of Upakarma Ayurveda said, “There has been a rising consciousness around Ayurveda in recent years. We, at Upakarma Ayurveda, have been building a connection with our consumers, and now with this partnership, the team is elated and is looking forward to widening our reach with Mankind Pharma backing us. With this partnership, I along with my co-founder, Parag Kaushik, are hopeful that quality ayurvedic solutions will reach far and wide”.

R&D driven Biotechnological Powerhouse Concord Biotech Files DRHP for IPO

Rare Enterprises and Quadria Capital-backed Concord Biotech files DRHP for IPO

Concord Biotech Limited, one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2021 has filed its Draft Red Herring Prospectus (DRHP) with the markets regulator, Securities and Exchange Board of India (SEBI), to raise funds through an initial public offering (IPO).

The issue with a face value of Re 1 per equity share is a complete offer for sale (OFS) aggregating to 20,925,652 equity shares by Helix Investment Holdings Pte. Limited. The offer also includes a reservation for a subscription by eligible employees.

The Offer is being made through the Book Building Process, wherein not more than 50% of the Offer shall be available for allocation to Qualified Institutional Buyers, not less than 15% of the Offer shall be available for allocation to Non-Institutional Bidders and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders.

As per the F&S report stated in its DRHP, Concord Biotech commands a market share of over 20% by volume in 2021 across identified fermentation-based API products including dactinomycin, sirolimus, tacrolimus, mycophenolate sodium, and cyclosporine. It supplies to over 70 countries including regulated markets such as the United States, Europe, Japan, and India.

The DRHP additionally states that Fermentation is a challenging process as it involves working with microbial strains and culture, controlling multiple process parameters, and performing various purification steps.

As of March 31, 2022, it had a portfolio of 56 brands and 65 products including 22 APIs and 43 formulations. In addition, it had 80 out-licensed formulations which they distributed in India under their brands. It has filed over 120 DMFs across several countries.

The Ahmedabad-based biopharma firm is amongst the few globally that has successfully and sustainably established and scaled up its fermentation-based API manufacturing capabilities. It has three production sites in the state of Gujarat located out of Valthera, Dholka, and Limbasi having a total installed fermentation capacity of 1,250 m3 .

Some of Concord Biotech's API clients include Intas Pharmaceuticals Limited and Glenmark Pharmaceuticals Limited. As of March 31, 2022, it had over 200 customers and its ten largest clients had a relationship with them for an average of nine years in FY22. It plans to increase its wallet share from its existing API customers and pursue growth in formulations in India, Emerging Markets, and the United States.

In India, CBL markets immunosuppressant, nephrology, and anti-infectives drugs for critical care, which they market under its own brands and through its sales force model. As of March 31, 2022, it offered formulations across 20 states and five union territories in India, covering over 1,500 government and corporate hospitals.

The company’s revenue from operations increased by 15.56% to Rs 712.93 crore for the Financial Year 2022 from Rs 616.94 crore for the Financial Year 2021, primarily due to an increase in the sales volume of its products to existing customers; sales to its new customers; and increase in prices of some of the products, which was partially offset by the decrease in prices of certain products, while profit for the financial year 2022 stood at Rs 174.93 crore.

The global small-molecule fermentation-based API market is expected to reach US $13 billion (Rs 966 billion) in 2026 at a CAGR of 3.6% from 2021 to 2026. The immunosuppressant drug market is expected to grow at a CAGR of 9.6% from 2021 to 2026. The Oncology drug market, the largest segment among the therapeutic areas in the API market, is expected to reach US $67 billion (Rs 4,978 billion) by 2026. The anti-infective market, one of the largest segments by revenue among the therapeutic areas in the API market, is expected to reach US $36 billion (Rs 2,675 billion) by 2026.

Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, and Jefferies India Private Limited are the book running lead managers and Link Intime India Private Limited is the registrar to the offer. The equity shares are proposed to be listed on BSE and NSE.

Scalable Cell Replacement Therapies Developer Firm Eyestem Raises $6.4 Mn in Series-A Led by Three Pharma Majors

Dr Jogin Desai Founder/CEO with Eyestem Team

Eyestem raises Series A round from Biological E, Alkem, NATCO, Kemwell promoters and existing investors - Kotak and Endiya

The investment will enable Eyestem to progress a treatment for Dry Age-related Macular Degeneration to the clinic

Eyestem, a Bengaluru-based cell therapy company, has raised $6.4 million (INR 51 Crore) in a Series A round led by three pharma majors - Biological E. Limited (BE), Alkem, NATCO and Anurag and Karan Bagaria, promoters of Kemwell Biopharma. Existing investors Endiya Partners and Kotak Private Equity also participated in this round, valuing Eyestem at $46.4 million (INR 371 Crore) post money.

Dr Jogin Desai, Founder and Chief Executive Officer of Eyestem said, “We started Eyestem with the sole purpose of being able to create cell therapy products at scale for diseases that devastate a large number of people in India and the world. The support of major Indian pharma companies who share our vision endorses our strategy of developing affordable innovation for patients worldwide. Post this funding, we will remain focussed on solidifying our cell therapy platform and moving our flagship product for Dry AMD through early clinical trials of an international standard”.

(L to R) Dr Rajarshi Pal, Dr Jogin Desai & Dr Rajani Battu, Founders of Eyestem

Eyecyte-RPE, the company’s patented flagship product, is an experimental treatment for Dry Age-Related Macular Degeneration (Dry AMD) and the company has other products in the pipeline for the treatment of incurable diseases affecting humanity. EyeCyte-RPE replaces damaged retinal pigment epithelium cells and is designed to restore sight for patients in early stages of Macular Degeneration or arrest loss of vision for those in later stages. The product is allogenic, administered by a surgical procedure and is patented in India and abroad. The company intends to file for a first in human trial for the product within a year in consultation with CDSCO and US FDA.

Rajeev Nannapaneni, CEO, NATCO Pharma Limited quoted, "We are very happy to be associated with Eyestem for their innovative work that services unmet needs of patients that have high impact for quality of life".

Commenting on the fundraise, Dr. Ramesh Byrapaneni, Managing Partner of Endiya Partners said, “Endiya partners is delighted to back such strong, globally competitive innovative start-ups and participate in the current funding round. The addition of leading pharma and biotech investors on our cap table is a great validation of the world class science that Eyestem is pursuing which can change millions of lives globally”.

Founded in 2016, by an experienced team of clinical research, regenerative medicine and ophthalmology experts, Eyestem is advised by a world-class Board and has built collaborations with other leaders in related scientific disciplines in India, UK, Japan and the United States. The long-term vision is to develop a scalable cell therapy platform to treat incurable diseases and democratize access to these newer technologies globally.

About Eyestem:

Headquartered in Bangalore and Delaware, Eyestem was founded by an experienced management team consisting of experts in clinical research, regenerative medicine and ophthalmology. Eyestem intends to be the benchmark for quality and affordability in cell therapies for targeted conditions. The company has received several prestigious awards and grants from the Department of Biotechnology, Government of India.

Zeon Lifesciences and Pharma Varsity DPSRU Ink MoU for Innovation in Nutraceuticals, Phytopharmaceuticals and Ayurveda

Zeon Lifesciences signs MoU with Delhi Pharmaceutical Sciences & Research University (DPSRU)

Aim to accelerate the development of new breakthroughs in the fields of nutraceuticals, phytopharmaceuticals, and Ayurveda

Zeon Lifesciences, India’s largest manufacturer of Nutraceutical and Herbal products, signs a Memorandum of Understanding (MoU) with Delhi Pharmaceutical Sciences & Research University (DPSRU) to establish collaboration for academic interaction and research advancement in the specified fields, as well as to share facilities and expertise. 

DPSRU and Zeon will conduct collaborative research activities at DPSRU encompassing pharmaceutical technology, synthesis and analytical techniques, pharmacotherapeutics, standardization of herbal actives and protocols adopted to comply with the regulatory milieu of the region/country concerned.

The goal of this collaboration is to conduct R&D projects to investigate formulation and product development in the fields of nutraceuticals, phytopharmaceuticals, and Ayurveda. Zeon Lifesciences Limited and DPSRU will be conducting clinical trials as per AYUSH or DCGI guidelines, applicable for selected formulations. Both entities will also conduct studies to compare the prevailing regulations, approaches and challenges while registration of drug products.

Commenting on the collaboration, Mr Suresh Garg, MD and Founder, Zeon Lifesciences: “Our collaboration with DSPRU aims to give our country's youth hands-on experience with the industry's ongoing development in the nutraceutical and phytopharmaceutical sectors. Millennials will have the opportunity to delve deeply because there has been an increase in curiosity, and as a result, they will grow rapidly in this field. We anticipate strong alliances, both domestically and globally.”

"We're looking forward to collaborating with Zeon Lifesciences on joint convergence research projects, as well as establishing and operating leading academic models in the emerging fields of nutraceuticals, phytopharmaceuticals, and Ayurveda. This collaboration will help both parties combine their complementary strengths and work towards establishing a thriving ecosystem for the future." Dr Ramesh Goyal, Vice-Chancellor, DPSRU added. 

With the vision to transform into a research-driven organisation, Zeon has collaborated with multiple reputed institutions across India for conducting quality research, pre-clinical & clinical study on these products, including NII, New Delhi, CCMB Hyderabad, IMS, Banaras Hindu University, SRM University, Chennai, Adesh University, Punjab, BITS Pilani, NIPER Mohali, and IIIM, CSIR, Jammu. Zeon has expressed an interest in collaborating on a variety of research-based products and technologies for the development of novel formulations and drug discovery.

Combating Counterfeit Drugs Using Blockchain Technology

This content has been authored by Ashwani Kumar, Vice President, Technology at Coforge (Formerly known as NIIT Technologies), an Indian MNC serving clients across the globe in IT solutions.

Featuring among one of the most unfortunate and malice practices of the modern age, counterfeit drugs open the can of worms of the pharmaceutical industry. Counterfeit drugs not only represent an inordinate amount of black money made through illicit means but also bring forth large scale health hazards for genuine patients. Great healthcare, infrastructure and availability of medicines at affordable prices are some pressing issues that every nation in the world is striving towards. 

Healthcare, just like education, is a basic right of every person. However, the greed of some people to make filthy money at the cost of human lives has poisoned the system. But with the advancement of technology, is it not possible to tackle and resolve this burning issue of counterfeit drugs using blockchain technology?

Well, quite a few tech companies are working in this field, for instance, Coforge, where Ashwani Kumar is the VP, technology. They have developed innovative applications that resolve the issue of counterfeit drugs to a large extent. We will talk more about what Coforge is doing in the latter half of this article. But first, let us briefly understand what blockchain technology is.

Understanding The Fundamentals of Blockchain Technology

This technology has been overtly spoken about in recent times. However, it remains to be established if its wide-scale implementation potential has been fully unveiled. As a matter of fact, a whole bunch of people consider blockchain technology synonymous with cryptocurrency or simply, Bitcoin. Only after understanding the underlying algorithms and working behind blockchain technology, could one begin to grasp the scope and potential that it holds. 

For the uninitiated, the simple way to understand blockchain technology is the following: A huge amount of data (transactions) are stored in blocks that are connected to each other via a chain that is the distributed ledger making the entire technology decentralised.

Since the proof of every single transaction on the blockchain is stored publicly, it becomes nigh impossible to edit or delete these entries. Each block gets its own hash code which is available to thousands of computers globally. Therefore, if a hacker were to invade the space to commit fraud, he has to change the hash codes of every block while every computer on the server will be notified of the same. That is the essence of blockchain technology that makes it so secure and transparent. Such relevant characteristics of any modern technology can find application in any field. That is why the question arises if blockchain technology can tackle the issue of counterfeit drugs? The short answer is yes!

Modern Technology As A Weapon Against Eliminating Counterfeit Drugs

With the issue of counterfeit drugs, fraud could happen at any stage right from manufacturing to distribution. Hence, comprehensive monitoring systems are needed to keep track of every aspect, starting from raw materials, manufacturing, to warehouses, carrying and forwarding agents, retailers, pharmacies and the consumers. For that, there are dedicated services by large IT firms like Coforge, which we had mentioned earlier. 

Ashwani Kumar has the domain expertise of years and the company has invested its resources in developing effective strategies to, ideally, eradicate counterfeit drugs. The application achieves this by recognising fake content of the QR code or barcode that is used extensively at every phase of the industry. 

The dashboard preview of the application pinpoints the offenders where the fraud has been committed. The customers are not mere spectators but also have the power to report such instances. The insights to the suspected activity are classified by region, category or product type in the form of visual graphs and charts. Using the in-house developed application based on blockchain technology, the users could track their orders to ensure the authenticity of the medicine.

In inference, there is sufficient evidence available in the form of companies like Coforge, to ascertain that blockchain technology could prove to be an effective weapon against the menace of counterfeit drugs. In an ideal scenario, more companies will come forward using this technology to resolve such grave issues of our times.

Hyderabad-based Biophore to Manufacture Indigenous Ingredients of Pfizer’s COVID Drug

Reduces dependence on China for Indian manufacturers

Paxlovid approved by US FDA for COVID treatment

Biophore India Pharmaceuticals has today announced that they have developed and started manufacturing the key intermediates of Nirmatrelvir, one of the active ingredients of Paxlovid, the latest anti-COVID therapy, approved by US FDA through the emergency use authorisation route. The manufacturing is being done in collaboration with Rakshit Group. This is expected to greatly reduce the dependence on imports, mainly from China, from where these intermediates are being procured currently. Biophore is also manufacturing Nirmatrelvir in a US FDA compliant facility and have announced that they will be filing for approval with DCGI soon.

Paxlovid’s breakthrough approval was given by the US FDA in Dec 2021 and is indicated for the treatment of mild-to-moderate COVID-19 in adults and paediatric patients as well and in those who are at high risk of progression to severe levels. It was the first oral pill that has been approved by US FDA and with a better safety profile than subsequently approved oral therapies. It is available in a co-pack of Nirmatrelvir and Ritonavir Tablets.

Dr. Jagadeesh Babu Rangisetty, CEO at Biophore, says, “The development and manufacturing of these intermediates is extremely complex and is significantly more challenging than earlier antivirals that have been indicated for COVID. We have developed the intermediates that are required for the manufacturing of this product from basic raw materials and have the manufacturing capabilities in place to produce high volumes, to the scale of multi tons, catering to Indian as well as global markets. As and when the product gets approved in India, we can ensure that the manufacturers of this product can be self-reliant from within India itself and not be dependent on imports, which can be tricky in terms of control of quality and supply”

Mr. Rameswara Rao Chandana, Chairman of Rakshit Group, says, “Rakshit Group’s subsidiary, Sainor Laboratories, is the largest manufacturer of Lithium HMDS in India with a capacity of 500 MT per month and has the facilities to handle cryogenic reactions. Manufacturing of these intermediates require extreme temperatures and large volumes of Lithium reagents and with the above infrastructure that we have, we are well placed to ensure that the requirements for the market can be met locally. With a strong partner such as Biophore, we believe this is a perfect synergy to get these products to the market quickly”.

About Biophore India Pharmaceuticals:

Founded in 2007, Biophore India Pharmaceuticals is an established pharmaceutical company that develops and manufactures niche pharmaceutical products for the generic industry. Biophore’s state-of-the-art, multipurpose manufacturing facilities in Visakhapatnam comply with cGMP standards and meet the requirements of US and EU Drug regulatory authorities. Its technology development center in Hyderabad is equipped with infrastructure that facilitates the entire process of drug research from conceptualization to regulatory submissions. Biophore’s portfolio is spread across 30 therapeutic segments and specializes in development and manufacturing of pharmaceutical actives for Oncology medication, Contrast and Diagnostic media. To date, the company has filed about more than 100 drug master files and 150 patents for its unique portfolio.

ENTOD Pharmaceuticals Set to Launch MOLENTOD™ (Molnupiravir), World’s 1st and Only Oral Anti-Viral COVID Treatment

Molnupiravir is the world’s first & only oral antiviral to be approved by the US FDA, UK MHRA & Indian CDSCO for treatment of COVID-19 (emergency restricted use). ENTOD Pharmaceuticals (including its subsidiaries and/or associate companies) today announced that it is launching a generic version of Molnupiravir under the brand MOLENTOD™ in India.

The Drugs Controller General of India (DCGI) last week, based on the review of clinical data of molnupiravir, approved molnupiravir for treatment of adult patients with Covid-19, with SpO2 > 93% and who have high risk of progression of the disease including hospitalisation or death.

“Emergency approval of Molnupiravir by DCGI is a very important decision taken by Indian Government and it will help to protect INDIA from the OMICRON wave” said Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals.

ENTOD Pharmaceuticals said that it’s aim is to make the product available as early as possible and that its first batch is already under production. MOLENTOD™ will be available at retail chemists, pharmacy chains, hospitals & online stores across India at an affordable price to patients with an MRP of Rs 649 per strip of 10 capsules, MOLENTOD™ it is very competitively priced against other similar products in the market.

“In the backdrop of steadily rising omicron cases now also in India, the launch of this oral anti-viral drug is another potent addition to India’s arsenal in its fight against the ongoing pandemic. That top global regulatory bodies including our own DGCI have given a go-ahead to this molecule demonstrates the potential efficacy rate of this drug. Also, the short duration nature of this treatment would ensure enhanced compliance helping the country avoid unnecessary hospitalizations or even deaths in the coming months,” said Ms. Anjula Masurkar, Clinical Director, Entod Pharmaceuticals.

The recommended dose of the drug is four capsules (800 mg) twice a day for five days. The duration of treatment of molnupiravir is much shorter compared to other therapies, which is a significant advantage as it reduces the pill burden and enhances compliance. Molnupiravir improves patient compliance for non-hospitalized patients and reduces the chance of hospitalization or death for high-risk populations.

Disclaimer:

Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

About ENTOD Pharmaceuticals Limited (CIN - U24230MH1981PLC025529):

ENTOD Pharmaceuticals is an international research-based pharmaceutical organisation with over three decades of pharmaceutical expertise in Ophthalmology, ENT, Dermatology & other speciality medicine. Globally we have over 200 products in our portfolio, a global field force of over 1000 and highly experienced Quality Assurance, Production and R&D teams. Our products are sold in over 55 countries including the EU, UK, Africa and Asia. Our quality systems are certified in Europe and our manufacturing quality standards adheres to international GMP norms. Our product range includes intracameral injections, eye drops, eye ointments, eye gels and soft gelatin capsules

For further information, please visit www.entodpharma.com & follow us on Twitter@EntodPharma

IIT Hyderabad Signs Pact with AI-based Drug Discovery Platform PharmCADD for the Co-Development of New Drugs

PharmCADD, a leading in-silico drug design company, and IIT Hyderabad also agreed to promote the alliance by jointly participating in global R&D projects.

Hyderabad, July 23, 2021: PharmCADD, AI and Physics/Quantum-based drug discovery company, has recently signed a Memorandum of Understanding (MOU) with the Indian Institute of Technology Hyderabad, a premier technical institute in the country, for co-developing new drugs and advancing the platform technology, pharmulatorTM.

PharmCADD has founded a local corporation in India last month and is intensively hiring competent Indian researchers. Under this MOU, IIT Hyderabad will provide PharmCADD with key members to conduct academic research in the field of AI, MD simulation, and quantum calculation for new drug development. PharmCADD and IIT Hyderabad also agreed to promote collaboration by jointly participating in global R&D projects.

India holds the world's third-largest AI capability, publishing 80,000 papers in the field of AI over the past five years.

“PharmCADD has designed and optimized the mRNA sequence for developing COVID 19 mRNA vaccine and the mRNA vaccine candidate has been recently applied for IND (Investigational New Drug) to begin clinical trial 1/2a study in KOREA. Based on this experience, we have expanded a vaccine developing platform and enhancing the platform technology with the aid of IITH's resources”, said Mr Taehyung Kwon, CEO, PharmCADD.

Expressing his delight on this momentous occasion Prof B S Murty, Director, IIT Hyderabad, said, “IIT Hyderabad is the only institute in the country with UG programs in both Biomedical Engineering and Biotechnology & Bioinformatics. IITH has dedicated faculty working many novel techniques & drugs. This global collaboration in the field of drug development will definitely strengthen our capabilities to develop novel formulations and make a healthier society”.

About PharmCADD

PharmCADD, founded in 2019, is the leading in-silico drug design company committed to accelerating the path for discovering and developing de-novo therapeutics for diseases more efficiently. Utilizing state-of-the-art technologies of deep neural networks, molecular dynamics simulation, quantum calculation, and network theory, Pharmulator™, their innovative artificial intelligence (AI)-based drug discovery platform, is poised to help global scientists tackle the most demanding challenges across the whole spectrum of the drug discovery process. At PharmCADD, they relentlessly work hard to become a reliable navigator and partner for drug discovery.

To know more, please visit: http://pharmcadd.com/company/